» Articles » PMID: 36185736

Covalent Organic Framework Nanomedicines: Biocompatibility for Advanced Nanocarriers and Cancer Theranostics Applications

Overview
Journal Bioact Mater
Date 2022 Oct 3
PMID 36185736
Authors
Affiliations
Soon will be listed here.
Abstract

Nanomedicines for drug delivery and imaging-guided cancer therapy is a rapidly growing research area. The unique properties of nanomedicines have a massive potential in solving longstanding challenges of existing cancer drugs, such as poor localization at the tumor site, high drug doses and toxicity, recurrence, and poor immune response. However, inadequate biocompatibility restricts their potential in clinical translation. Therefore, advanced nanomaterials with high biocompatibility and enhanced therapeutic efficiency are highly desired to fast-track the clinical translation of nanomedicines. Intrinsic properties of nanoscale covalent organic frameworks (nCOFs), such as suitable size, modular pore geometry and porosity, and straightforward post-synthetic modification via simple organic transformations, make them incredibly attractive for future nanomedicines. The ability of COFs to disintegrate in a slightly acidic tumor microenvironment also gives them a competitive advantage in targeted delivery. This review summarizes recently published applications of COFs in drug delivery, photo-immuno therapy, sonodynamic therapy, photothermal therapy, chemotherapy, pyroptosis, and combination therapy. Herein we mainly focused on modifications of COFs to enhance their biocompatibility, efficacy and potential clinical translation. This review will provide the fundamental knowledge in designing biocompatible nCOFs-based nanomedicines and will help in the rapid development of cancer drug carriers and theranostics.

Citing Articles

Hybrid Nanoplatforms Based on Photosensitizers and Metal/Covalent Organic Frameworks for Improved Cancer Synergistic Treatment Nano-Delivery Systems.

Magadla A Molecules. 2025; 30(4).

PMID: 40005193 PMC: 11858586. DOI: 10.3390/molecules30040884.


Engineered bacterial membrane biomimetic covalent organic framework as nano-immunopotentiator for cancer immunotherapy.

Yang Q, Wang Y, Wang S, Song A, Wang W, Zhang L Bioact Mater. 2025; 47:283-294.

PMID: 39925708 PMC: 11803166. DOI: 10.1016/j.bioactmat.2025.01.018.


Metal-based smart nanosystems in cancer immunotherapy.

Luo Y, He X, Du Q, Xu L, Xu J, Wang J Exploration (Beijing). 2024; 4(6):20230134.

PMID: 39713201 PMC: 11655314. DOI: 10.1002/EXP.20230134.


Synergistic SDT/cuproptosis therapy for liver hepatocellular carcinoma: enhanced antitumor efficacy and specific mechanisms.

Sun Y, Chen Y, Wu B, Li H, Wang Y, Wang X J Nanobiotechnology. 2024; 22(1):762.

PMID: 39696275 PMC: 11657978. DOI: 10.1186/s12951-024-02995-3.


In Situ Transformable Nanoparticle Effectively Suppresses Bladder Cancer by Damaging Mitochondria and Blocking Mitochondrial Autophagy Flux.

Lv Y, Song B, Yang G, Wang Y, Wu Z, Si M Adv Sci (Weinh). 2024; 12(5):e2409425.

PMID: 39651805 PMC: 11791963. DOI: 10.1002/advs.202409425.


References
1.
Shi J, Kantoff P, Wooster R, Farokhzad O . Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2016; 17(1):20-37. PMC: 5575742. DOI: 10.1038/nrc.2016.108. View

2.
Hu Q, Huang Z, Duan Y, Fu Z, Liu B . Reprogramming Tumor Microenvironment with Photothermal Therapy. Bioconjug Chem. 2020; 31(5):1268-1278. DOI: 10.1021/acs.bioconjchem.0c00135. View

3.
Hwang E, Jung H . Metal-organic complex-based chemodynamic therapy agents for cancer therapy. Chem Commun (Camb). 2020; 56(60):8332-8341. DOI: 10.1039/d0cc03012k. View

4.
Dai Y, Xu C, Sun X, Chen X . Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chem Soc Rev. 2017; 46(12):3830-3852. PMC: 5521825. DOI: 10.1039/c6cs00592f. View

5.
Li J, Huang J, Lyu Y, Huang J, Jiang Y, Xie C . Photoactivatable Organic Semiconducting Pro-nanoenzymes. J Am Chem Soc. 2019; 141(9):4073-4079. DOI: 10.1021/jacs.8b13507. View